Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-01-31 4:10 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 6,375,000 9.800% | 6,375,000 (New Position) | View |
| 2024-01-31 4:10 pm Sale | 13G | Autolus Therapeutics plc AUTL | Tetragon Financial Management LP | 8,000,000 4.600% | -1,461,883 (-15.45%) | View |
| 2023-03-20 09:13 am Purchase | 13G | Autolus Therapeutics plc AUTL | Tetragon Financial Management LP | 9,461,883 5.500% | 9,461,883 (New Position) | View |
| 2023-01-31 4:15 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 4,000,000 6.200% | 300,000 (+8.11%) | View |
| 2022-12-08 12:42 pm Unchanged | 13D | APPLIED GENETIC TECHNOLOGIES CORP AGTC | Tetragon Financial Management LP | 0 0.000% | 0 (Unchanged) | View |
| 2022-03-21 11:10 am Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 3,700,000 6.100% | 3,700,000 (New Position) | View |